Introduction
Nuclear imaging techniques such as single photon emission CT (SPECT) and positron emission tomography (PET) have been used for many years to image molecular pathology in the myocardium [1•]. More recently, magnetic resonance and fl uorescence-based techniques have been added to the molecular imaging armamentarium [2•,3] , and a growing body of work with these modalities in the imaging of myocardial injury has emerged [4] . The use of magnetic, fl uorescent, or combined magnetofl uorescent platforms has added several new dimensions to molecular imaging of the myocardium: in vivo images can now be correlated with fl ow cytometry and fl uorescence microscopy of the imaging agents, thus providing a detailed cellular understanding of probe uptake. In addition, activatable imaging agents can now be detected in vivo, providing a local assay of enzyme activity. Perhaps in no other area of the body, however, is the opportunity to integrate anatomic, physiologic, and molecular imaging into a single comprehensive imaging strategy as great as it is in the myocardium. The realization of this goal will undoubtedly be pursued via multiple strategies, each with its merits and disadvantages. This article highlights recent advances with magnetofl uorescent imaging agents in the myocardium, focusing largely on ischemic heart disease and its sequelae.
Integrated Imaging Approach
The properties of molecular MRI and fl uorescence imaging are highly complementary [4] . Physiologic parameters of interest in the myocardium include ventricular volumes, myocardial mass, ejection fraction, contractility, strain, perfusion, viability, and hemodynamics. Although at present fl uorescence techniques are unable to image most of these parameters, MRI measures them with exceptional accuracy. Molecular MRI agents can also be detected in vivo with signifi cantly better spatial resolution than that obtainable with noninvasive fl uorescence techniques. However, fl uorescence imaging agents provide excellent sensitivity (picomolar or better) and are ideally suited to activatable and multispectral (multi-target) approaches [3] . A compelling case can thus be made to, whenever possible, pursue a dual-modality magnetofl uorescent approach for molecular imaging of the myocardium.
Magnetic nanoparticles such as gadolinium-loaded liposomes, gadolinium-containing micelles, and dextran-coated iron-oxide nanoparticles can be labeled with a fl uorochrome without signifi cantly changing the pharmacokinetics of the nanoparticle. Conventional gadolinium chelates, however, are frequently smaller than the fl uorochrome and the pharmacokinetics of a joint construct can thus easily become dominated by the properties (size, charge, protein binding) of the fl uorochrome. When fl uorescent labeling is not feasible, molecular specifi city in the myocardium can be confi rmed using either scrambled versions of the probe or transgenic animal models (see collagen-binding and myeloperoxidaseactivatable agents below).
I Molecular Imaging

Activatable Imaging Agents
One of the distinct advantages of both magnetic and fl uorescent imaging agents is the ability to produce activatable imaging constructs with these platforms. While radioisotope-labeled probes emit radiation regardless of their state (they are always active), the fl uorescence and magnetic properties of an imaging agent can be highly modulated. Activation of magnetofl uorescent constructs can result from enzymatic cleavage of the agent into a more active form [5] , or by assembly/disassembly of the agent [6] . To date, the latter strategy (assembly/disassembly) has been used successfully to image both activatable near-infrared (NIR) fl uorochromes and novel gadolinium chelates in the myocardium [7,8••,9••] .
Activatable NIR fl uorochromes generally consist of two fl uorescent moieties held in close proximity to each other by a peptide linker. In this confi guration the fl uorochromes quench each other, producing no fl uorescence. Cleavage of the recognition sequence in the peptide linker by the specifi c enzyme of interest separates the two fl uorescent moieties from each other, eliminating quenching and producing robust fl uorescence [10] . Activatable magnetic resonance agents likewise rely on assembly/disassembly of the individual chelates or nanoparticles, which results in a detectable change in the magnetic relaxivity of the agent [6,11•,12] . Importantly, both activatable magnetic and fl uorescence imaging agents report the local activity of an enzyme of interest, and not merely its presence. This provides additional biological information to that obtained when labeled affi nity ligands are used to bind to a particular site on an enzyme, which provides no information regarding the activity of the enzyme.
Pharmacokinetic and Technical Considerations
Molecular imaging of the myocardium requires the imaging agent to be small enough to penetrate the capillary membrane and enter the interstitial space. Magnetic nanoparticles, such as cross-linked iron oxide (CLIO), are 30 to 50 nm in size and able to penetrate both the normal and ischemic capillary membrane [13] . Smaller gadolinium-labeled liposomes and micelles are also able to do this, but larger liposomes remained confi ned to the intravascular space. Once in the interstitial space, the imaging agent then needs to remain inert and not bind nonspecifi cally to either cardiomyocytes or any of the surrounding connective tissue elements. CLIO and analogous iron-oxide nanoparticles are coated with dextran and thus remain inert and nonreactive in the interstitial space of the myocardium [14] . The potential for nonspecifi c binding of micelles and liposomes is of greater concern, and a potential disadvantage of the use of these agents in the myocardium.
The ideal blood half-life of an imaging agent designed for targeted myocardial imaging ranges from 1 to 4 hours. This provides adequate time for the agent to penetrate the capillary membrane and detect its molecular target, while minimizing background circulation of the probe. High concentrations of radiolabeled SPECT and PET imaging agents in the left ventricular blood pool or lungs can adversely affect the dynamic range of the imaging experiment [15] , or require the imaging readout to be delayed. MRI, however, does not suffer from this limitation and the myocardial uptake of an agent can usually be accurately imaged independent of the blood pool signal. In addition, if required, the blood pool signal can be modifi ed or nulled through the use of inversion prepulses, diffusion-encoded stimulated echo sequences, and other black blood techniques [14, 16] .
Fluorescence imaging agents that are not quenched in their baseline state can, like radioactive probes, produce a high signal in the blood pool. However, if background activation of a quenched fl uorochrome in the blood pool is minimal, imaging of the signal generated by probe activation in the myocardium can be performed soon after the injection of the agent. The high hemoglobin concentration in the blood pool signifi cantly attenuates light in the visible spectrum. Signal generated by a fl uorochrome in the myocardium in the visible range of the spectrum may thus be signifi cantly attenuated, precluding accurate detection [3] . The attenuation of light is lowest in the NIR portion of the spectrum, and in vivo fl uorescent imaging of the myocardium is optimally performed in this range of the spectrum [3] . Background autofl uorescence in the myocardium tends to be fairly high, particularly in recently infarcted myocardium. However, autofl uorescence is also lowest in the NIR, providing additional impetus for the use of fl uorochromes in this range of the spectrum [3] . The use of NIR fl uorochromes, coupled with advances in detector technology and reconstruction algorithms, has allowed noninvasive threedimensional fl uorescence tomography of the myocardium to be performed in mice in vivo [8••,17••] . Localization of the fl uorescent hot spot signal to the myocardium can be performed by simultaneously imaging a second blood pool agent, detecting the left ventricular blood pool through the creation of absorption maps, or by fusing the fl uorescence image with an anatomical imaging modality such as MRI or x-ray CT [17••] .
Magnetofl uorescent Imaging in Ischemic Heart Disease
Ischemic heart disease remains a major public health problem despite advances in the primary and secondary prevention of atherosclerosis. Although major strides have been made in establishing and maintaining patency of the infarct-related artery, the prevention of reperfusion injury and heart failure remain problematic. Magnetofl uorescent
